scholarly journals A Comparison between18F-FDG PET/CT Imaging and Biological and Radiological Findings in Restaging of Hepatoblastoma Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Angelina Cistaro ◽  
Giorgio Treglia ◽  
Manuela Pagano ◽  
Piercarlo Fania ◽  
Valentina Bova ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Disease Recurrence ◽  
Diagnostic Value ◽  
Needle Aspiration ◽  
Diagnostic Information ◽  
Disease Extent ◽  
Pet Ct ◽  
Negative Findings ◽  
Definition Of ◽  
Fdg Pet Ct

Background. In this study we retrospectively evaluated if18F-FDG-PET/CT provided incremental diagnostic information over CI in a group of hepatoblastoma patients performing restaging.Procedure. Nine patients (mean age: 5.9 years; range: 3.1–12 years) surgically treated for hepatoblastoma were followed up by clinical examination, serumα-FP monitoring, and US. CI (CT or MRI) and PET/CT were performed in case of suspicion of relapse. Fine-needle aspiration biopsies (FNAB) were carried out for final confirmation if the results of CI, PET/CT, and/orα-FP levels were suggestive of relapse. PET/CT and CI findings were analyzed for comparison purposes, using FNAB as reference standard.Results.α-FP level was suggestive of disease recurrence in 8/9 patients. Biopsy was performed in 8/9 cases. CI and PET/CT resulted to be concordant in 5/9 patients (CI identified recurrence of disease, but18F-FDG-PET/CT provided a better definition of disease extent); in 4/9 cases, CI diagnostic information resulted in negative findings, whereas PET/CT correctly detected recurrence of disease.18F-FDG-PET/CT showed an agreement of 100% (8/8) with FNAB results.Conclusions.18F-FDG-PET/CT scan seems to better assess HB patients with respect to CI and may provide incremental diagnostic value in the restaging of this group of patients.

scholarly journals CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence

2014 ◽  
Vol 53 (04) ◽  
pp. 131-138 ◽  
Author(s):  
V. Kruse ◽  
C. Van de Wiele ◽  
M. Borms ◽  
A. Maes ◽  
H. Pottel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Roc Curve ◽  
Fdg Pet ◽  
Her2 Status ◽  
Disease Extent ◽  
Ca 15.3 ◽  
Pet Ct ◽  
Negative Findings ◽  
Fdg Pet Ct ◽  
Blood Volumes

SummaryIn breast cancer CA 15.3 is considered the tumour marker of choice. CA 15.3 is directly related to the disease extent and to hormone status (estrogen receptor ER+/ ER-, progesterone receptor PR+/PR-). This study was designed to assess the impact of disease extent, hormone receptor and HER2-status, and circulating blood volume on the area-under the ROC-curve of CA 15.3 to separate FDG PET positive from negative findings. Patients, methods: We retrospectively evaluated 379 FDG PET/CT examinations performed in 80 patients with breast cancer. Blood volumes were derived using the formulas by Nadler and multiplied by their corresponding CA 15.3 measurement. Results: ROC-curve analysis revealed an AUC of 0.695 (p = 0.0001) for CA 15.3 to separate FDG PET positive from negative findings. AUC measurements to separate normal scan find-ings from loco-regional disease and meta- static disease were 0.527 (p = 0.587) and 0.732 (p = 0.0001), respectively. AUC measurements for CA 15.3 to separate positive from negative FDG PET findings, in ER+ and ER- patients, were respectively 0.772 (p = 0.0001) and 0.596 (p = 0.143). AUC measurements for CA 15.3 to separate positive from negative FDG PET findings, in PR+ and PR- patients, were respectively 0.675 (p = 0.0001) and 0.694 (p = 0.0001). In HER2-positive and -negative patients, the AUC measurements were respectively 0.594 (p = 0.178) and 0.701 (p = 0.0001) to separate positive from negative FDG PET findings. Conclusion: The AUC for CA 15.3 measurements to separate FDG PET positive from negative findings in breast cancer patients with suspected recurrence proved to be directly related to the extent of the recurrent disease and hormone receptor status and inversely related to HER2-status. Correcting CA 15.3 measurements for blood volumes did not impact the AUC.

The Diagnostic Value of FDG PET/CT and Thin-Slice High-Resolution Chest CT in Pulmonary Intravascular Metastasis

2021 ◽  
pp. 1-7
Author(s):  
Yu Ji ◽  
Chunchun C. Shao ◽  
Yong Cui ◽  
Kai Cui ◽  
Guangrui R. Shao ◽  
...  
Keyword(s):  
High Resolution ◽  
Fdg Pet ◽  
Diagnostic Value ◽  
Chest Ct ◽  
Thin Slice ◽  
Pet Ct ◽  
Fdg Pet Ct

Diagnostic value of [18F]-FDG PET/CT in children with fever of unknown origin or unexplained signs of inflammation

2009 ◽  
Vol 37 (1) ◽  
pp. 136-145 ◽  
Author(s):  
Niklas Jasper ◽  
Jan Däbritz ◽  
Michael Frosch ◽  
Markus Loeffler ◽  
Matthias Weckesser ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Fever Of Unknown Origin ◽  
Unknown Origin ◽  
Diagnostic Value ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Diagnostic value of 18F-FDG PET/CT for atypical hepatic hemangioma

2021 ◽  
Author(s):  
Jianlin Wang ◽  
Aiqi Shi ◽  
Xiaofang Ding ◽  
Jiangyan Liu
Keyword(s):  
Fdg Pet ◽  
Diagnostic Value ◽  
Hepatic Hemangioma ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

18F-FDG PET/CT in the detection of asymptomatic malignant melanoma recurrence

2017 ◽  
Vol 56 (03) ◽  
pp. 83-89 ◽  
Author(s):  
Ismaheel Lawal ◽  
Thabo Lengana ◽  
Kehinde Ololade ◽  
Tebatso Boshomane ◽  
Florette Reyneke ◽  
...  
Keyword(s):  
Lymph Node ◽  
Malignant Melanoma ◽  
Diagnostic Accuracy ◽  
Fdg Pet ◽  
Disease Recurrence ◽  
Nodal Metastasis ◽  
Primary Lesion ◽  
Pathologic Features ◽  
Pet Ct ◽  
Fdg Pet Ct

SummaryAim: To evaluate the diagnostic accuracy of FDG PET/CT in the detection of asymptomatic recurrence in patients with malignant melanoma who have had resection of their primary lesion. We also aimed to determine the pattern and factors predisposing to disease recurrence. Methods: Patients with malignant melanoma who have had surgical resection of their disease and without any clinical evidence of disease recurrence were followed- up with FDG PET/CT. The diagnostic accuracy of FDG PET/CT, pattern of recurrence and factors predictive of disease recurrence were determined. Results: A total of 144 patients were followed-up for a median period of 50.50 months. Asymptomatic recurrence was seen in 37 patients (25.7 %) with a median time to recurrence of 20 months. Lymph node was the commonest site of asymptomatic recurrence. Sex, tumour depth, histology type and presence of nodal metastasis were significant predictors of tumour recurrence. Age, race, site of primary lesion, type of lymph node resection were not significant predictors of disease recurrence. Race has a significant effect on the histological subtype of tumour (nodular maligna was more common in Caucasian while acral lentiginous was more prevalent in the Blacks) and the site of the primary lesion (lower limb in Blacks and trunk in Caucasians). Sensitivity, specificity and accuracy of FDG PET/CT for the detection of disease recurrence were 94.5 %, 87.6 % and 89.6 % respectively. Conclusion: FDG PET/CT is a suitable modality for early detection of asymptomatic recurrence of malignant melanoma. Asymptomatic recurrence most commonly occurs in lymph nodes. Sex, nodal metastasis and tumour pathologic features are predictors of recurrence.

scholarly journals Diagnostic Value of FDG PET-CT Quantitative Parameters and Deauville-Like 5 Point-Scale in Predicting Malignancy of Focal Thyroid Incidentaloma

2019 ◽  
Vol 6 ◽  
Author(s):  
Philippe Thuillier ◽  
David Bourhis ◽  
Nathalie Roudaut ◽  
Geneviève Crouzeix ◽  
Zarrin Alavi ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Diagnostic Value ◽  
Point Scale ◽  
Thyroid Incidentaloma ◽  
Quantitative Parameters ◽  
Pet Ct ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document